Get Our FREE Newsletter

Sign Up

DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

Spread the love

DiaMedica Therapeutics Inc. DMAC announced that it initiated a pivotal phase II/III study — ReMEDy2 — to evaluate its recombinant kallikrein-1 (KLK1) protein candidate, DM199, as a potential treatment of acute ischemic stroke (AIS). Data from this study will support a bio

This post was originally published on this site